Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting

NEXT STORY
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
PREV STORY
Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Enzymotec Ltd. Reports Third Quarter 2015 Results

Earns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in ...

author_avatar
NASDAQ Market News

Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

Study Published in The New England Journal of Medicine Demonstrates Patients Experience Fewer Disruptions to Dialysis Therapy When Treated with Medtronic Drug-Coated Balloon

author_avatar
NASDAQ Market News